Monograph Capital

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Nocion Therapeutics is a biopharmaceutical company developing novel therapies called 'nocions' that selectively target actively firing nociceptors to provide relief for serious conditions such as cough, itch, pain, and inflammation.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

ODAIA is a technology company offering an AI-powered customer data platform for the life sciences industry. Its platform blends data analysis, process mining, and artificial intelligence to deliver goal-driven commercial insights and automate processes as a software-as-a-service. It supports personalized selling by helping pharmaceutical teams map customer journeys and optimize engagement to ensure therapeutics reach patients who need them.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

RegASK is a global RegTech company that uses artificial intelligence to monitor regulatory changes and ESG issues in real time. The platform provides instant alerts and a full range of services, including real-time regulatory monitoring, risk prediction, compliance support, path-to-market, path-to-claim, product registration, and regulatory strategy for products in the food, dietary supplement, cosmetic, personal care, and medical device industries. The company helps organizations reduce the time and cost of regulatory research and stay ahead of evolving requirements across global markets. RegASK was founded in 2017 by Caroline Shleifer and is headquartered in Singapore.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.